Stockscreener 앱 받기
1.86
6.29%
0.11
시간 외 거래:
1.89
0.03
+1.61%
전일 마감가:
$1.75
열려 있는:
$1.79
하루 거래량:
394.87K
Relative Volume:
0.48
시가총액:
$79.34M
수익:
$55,200
순이익/손실:
$-21.24M
주가수익비율:
-3.1606
EPS:
-0.5885
순현금흐름:
$-19.37M
1주 성능:
+14.11%
1개월 성능:
+6.29%
6개월 성능:
-9.71%
1년 성능:
+10.06%
1일 변동 폭
$1.769
$1.89
1주일 범위
$1.63
$1.89
52주 변동 폭
$1.41
$4.34
게인 테라퓨틱스 Stock (GANX) Company Profile
명칭
Gain Therapeutics Inc
전화
(301) 500-1556
주소
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.86 | 74.64M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
게인 테라퓨틱스 Stock (GANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-08-14 | 재개 | Oppenheimer | Outperform |
| 2021-04-12 | 개시 | BTIG Research | Buy |
| 2021-04-12 | 개시 | Oppenheimer | Outperform |
게인 테라퓨틱스 주식(GANX)의 최신 뉴스
Gain Therapeutics Inc (GANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GANX|Gain Therapeutics Inc|Price:1.750|Chg%:-0.070 - TradingKey
Gain Therapeutics Inc (GANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gain Therapeutics Inc (GANX) Institutional Confidence - TradingKey
TradingKey - TradingKey
Form 4 Gain Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Gain Therapeutics (GANX) awards director 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards director 25,000 stock options - Stock Titan
Gain Therapeutics (GANX) director granted 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (NASDAQ: GANX) awards director 25,000 stock options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards director 25,000 options at $1.68 - Stock Titan
Gain Therapeutics (GANX) awards 25,000 options to director at $1.68 strike - Stock Titan
Gain Therapeutics Extends Cash Runway Into 2027 Operations - TipRanks
Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Terenzio Ignoni as COO - Moomoo
Gain Therapeutics plans phase 2 Parkinson’s study in Q3 2026 By Investing.com - Investing.com South Africa
Gain Therapeutics says cash runway extends into Q2 2027 amid Phase 2 start plans - TradingView
Gain Therapeutics plans phase 2 Parkinson’s study in Q3 2026 - Investing.com
Gain Therapeutics (NASDAQ: GANX) sees cash funding into Q2 2027 - Stock Titan
Gain Therapeutics advances Parkinson's drug rex... - Pluang
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update - marketscreener.com
Gain Therapeutics Reports 81% Biomarker Drop in Some Patients - Stock Titan
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Gain Therapeutics (GANX) Q1 2026 earnings summary - Quartr
Gain Therapeutics (GANX) The 38th Annual Roth Conference Summary - Quartr
Gain Therapeutics (GANX) Proxy filing Summary - Quartr
Gain Therapeutics (GANX) Q4 2025 earnings summary - Quartr
GANX Q1 2026 Earnings: Narrower Loss Per Share Beats Estimates Amid Pre-Revenue PhaseQuarterly Financial Update - dars.gov.et
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease - BioBuzz
With new FDA green light for developer, Parkinson’s clinical trial to launch soon - Parkinson's News Today
Gain Therapeutics Inc. (GANX) Declines Sharply as Key Support Level Comes into FocusElliott Wave Count - dars.gov.et
Gain Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss but Shares DeclineGuidance Update - dars.gov.et
Enterprise value to EBIT forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Good GAIN - Moomoo
GANX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval - Investing.com
Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained - TipRanks
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Gain Therapeutics Price Target Maintained With a $5.00/Share by BTIG - Moomoo
Price to sales forward of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Number of shareholders of Gain Therapeutics, Inc. – NASDAQ:GANX - TradingView
Gain Therapeutics Receives FDA Clearance to Initiate Phase 2 Trial of GT-02287 for Parkinson’s Disease - Minichart
Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines - Moomoo
Gain Therapeutics (GANX) Jumps 13% to $1.98 – Support and Resistance Levels in FocusPSAR Stop - dars.gov.et
Why Is GANX Stock Rallying 22% After Hours? - Asianet Newsable
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug By Investing.com - Investing.com India
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial - TipRanks
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease - marketscreener.com
Gain Therapeutics receives FDA clearance for Parkinson’s drug trial By Investing.com - Investing.com Nigeria
게인 테라퓨틱스 (GANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):